These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 8714583

  • 21. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H.
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [Abstract] [Full Text] [Related]

  • 22. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H.
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):806-8. PubMed ID: 19194363
    [No Abstract] [Full Text] [Related]

  • 23. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
    Watanapokasin R, Sanmund D, Winichagoon P, Muta K, Fucharoen S.
    Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia.
    Thein SL.
    Blood Rev; 2012 Apr; 26 Suppl 1():S35-9. PubMed ID: 22631042
    [Abstract] [Full Text] [Related]

  • 26. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
    Ajanta H, Chakraborty S, Madhusnata D, Bhattacharya DK, Manisha D.
    J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia.
    Lowrey CH, Nienhuis AW.
    N Engl J Med; 1993 Sep 16; 329(12):845-8. PubMed ID: 7689171
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia.
    Rigano P, Manfré L, La Galla R, Renda D, Renda MC, Calabrese A, Calzolari R, Maggio A.
    Hemoglobin; 1997 May 16; 21(3):219-26. PubMed ID: 9140718
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
    Patthamalai P, Fuchareon S, Chaneiam N, Ghalie RG, Chui DH, Boosalis MS, Perrine SP.
    Blood; 2014 Mar 20; 123(12):1956-7. PubMed ID: 24652964
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chemotherapy and hemoglobin F synthesis in sickle cell disease.
    Dover GJ, Charache S.
    Ann N Y Acad Sci; 1989 Mar 20; 565():222-7. PubMed ID: 2476061
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.